SHR-1210 in Recurrent/Metastatic Nasopharyngeal Carcinoma Who Have Received Previous At Least Two Lines of Chemotherapy.

The primary objective of this phase 2 study is to assess objective response rate of SHR-1210 in patients with R/M NPC. The secondary objective is to observe the duration of response, progression free survival, time to response, overall survival and safety of SHR-1210 in R/M NPC. ADA is also investigated.

Inclusion criteria

• Histologically confirmed Recurrent/Metastatic Nasopharyngeal Carcinoma (WHO type II-III);
• Stage IVb R/M NPC failed from first-line platinum based chemotherapy and second-line chemotherapy;
• ECOG performance status of 0 or 1;
• Life expectancy ≥ 12 weeks;
• Subjects must have measurable disease by CT or MRI per RECIST 1.1 criteria;
• Can provide either a newly obtained or archival tumor tissue sample;
• Adequate laboratory parameters during the screening period as evidenced by the following:

• Absolute neutrophil count ≥ 1.5 × 10^9/L ;
• Platelets ≥ 90 × 10^9/L;
• Hemoglobin ≥ 9.0 g/dL;
• Serum albumin ≥ 2.8g/dL;
• Total bilirubin (TBIL) ≤ 1.5 × upper limit of normal (ULN), ALT and AST ≤ 1.5×ULN
• Creatinine clearance≥50 mL/min;
• Female of child bearing potential, a negative urine or serum pregnancy test result within 72 h before study treatment. Participants of reproductive potential must be willing to use adequate contraception for the course of the study through 60 days after the last dose of SHR-1210. Male subjects with WOCBP partner must be willing to use adequate contraception for the course of the study through 120 days after the last dose of SHR-1210;
• Subjects must be willing to participate in the research and sign an informed consent form (ICF);

Exclusion criteria

• Subjects with any active autoimmune disease or history of autoimmune disease;
• Subjects having clinical symptoms of metastases to central nervous system (such as cerebral edema, requiring steroids intervention, or brain metastasis progression);
• Has a known additional malignancy within the last 5 years before study treatment with the exception of curatively treated basal cell and squamous cell carcinoma of the skin and/or curatively resected in-situ cervical and/or breast cancers;
• Uncontrolled clinically significant heart disease, including but not limited to the following: (1) > NYHA II congestive heart failure; (2) unstable angina, (3) myocardial infarction within the past 1 year; (4) clinically significant supraventricular arrhythmia or ventricular arrhythmia requirement for treatment or intervention;
• Concurrent medical condition requiring the use of cortisol (>10mg/day Prednisone or equivalent dose) or other systematic immunosuppressive medications within 14 days before the study treatment. Except: inhalation or topical corticosteroids. Doses > 10 mg/day prednisone or equivalent for replacement therapy;
• Has received prior anti-cancer monoclonal antibody (mAb), chemotherapy, targeted small molecule therapy within 4 weeks prior to first dosing or not recovered to ≤CTCAE 1 from adverse events (except for hair loss or neurotoxic sequelae from prior platinum therapy) due to a previously administered agent. Palliative irradiation should be ended 2 weeks before first dosing;
• Active infection or an unexplained fever > 38.5°C before two weeks of first dosing (subjects with tumor fever may be enrolled at the discretion of the investigator);
• Known Human Immunodeficiency Virus (HIV) infection、active Hepatitis B or Hepatitis C;
• Currently participating or has participated in a study within 4 weeks of the first dose of study medication;
• Received a live vaccine within 4 weeks of the first dose of study medication. Pregnancy or breast feeding;
• Received a systematic antibiotics within 4 weeks of the first dose of study medication.

Pregnancy or breast feeding.

• Prior therapy with a PD-1, anti-PD-Ligand 1 (PD-L1) or CTLA-4 agent;
• Subjects are known to have a history of psychiatric substance abuse, alcoholism, or drug addiction;
• Pregnancy or breast feeding;
• According to the investigator, other conditions that may lead to stop the research.